Kumar Neil 的 Form 4 申報
BridgeBio Pharma, Inc.（BBIO），2026/2/23 申報
- 申報編號
- 0001470831-26-000214
- 申報時間
- 2026/2/23
- 交易日
- 2026/2/19
- 申報延遲
- 4 天
- 10b5-1 計畫
- 有勾選
這份申報列了 3 筆非衍生性交易。公開市場賣出合計 $200.3 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Kumar NeilCIK 0001742485 | 董事、高階主管（執行長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
Represents the weighted average sale price of the shares sold from $70.61 to $71.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F3
Represents the weighted average sale price of the shares sold from $71.61 to $72.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F4
Represents the weighted average sale price of the shares sold from $72.61 to $72.86 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。